William Nabours
Family Medicine · Lake Charles, LANPI 1659371193
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 499 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 16.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,047 and has fallen 95.2% since, to $98 in 2024. Among family medicine clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 499 payments — averaging $15.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$919
- AstraZeneca$816
- Lilly USA, LLC$645
- Amgen$486
- Merck$475
- plus $3K from 22 others
Across 21 payments — averaging $149,945 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$3.1M
- AstraZeneca$45K
What the payments were for
- Food & beverage$7,642100%
- Education$240%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 82 | $1,235 |
| Novo Nordisk | 64 | $919 |
| AstraZeneca | 40 | $816 |
| Lilly USA, LLC | 46 | $645 |
| Amgen | 36 | $486 |
| Merck | 29 | $475 |
| Pfizer | 38 | $401 |
| Astellas Pharma US Inc | 22 | $382 |
| GSK | 17 | $302 |
| Amarin Pharma, Inc. | 15 | $300 |
| Esperion Therapeutics, Inc. | 15 | $246 |
| Sanofi-aventis U.S. LLC | 17 | $242 |
| Kowa Pharmaceuticals America, Inc. | 13 | $221 |
| Boehringer Ingelheim | 12 | $187 |
| Novartis | 9 | $144 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $144 |
| Sunovion Pharmaceuticals Inc. | 10 | $123 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $90 |
| Avanir Pharmaceuticals, Inc. | 6 | $87 |
| Bayer | 2 | $44 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $42 |
| Biohaven Pharmaceuticals, Inc. | 2 | $36 |
| Johnson & Johnson | 2 | $32 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Shire North American Group Inc | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYMBICORT$238
- FARXIGA$238
- BREZTRI AEROSPHERE$123
How this compares
$7,667 in reported general payments places this provider in the 90th percentile of 1,469 family medicine providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SynthroidLevothyroxine Sodium | 12 | $801 |
| Atorvastatin Calcium | 40 | $384 |
| Metoprolol Succinate | 15 | $365 |
| Rosuvastatin Calcium | 14 | $318 |
| Ezetimibe | 12 | $217 |
| Escitalopram Oxalate | 16 | $153 |
| Gabapentin | 11 | $114 |
| Simvastatin | 16 | $110 |
| Metformin Hcl | 12 | $99 |
| Hydrochlorothiazide | 18 | $93 |
| Amlodipine Besylate | 11 | $64 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieSynthroid | $1,235 | $80112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Lake Charles
- Joshua WhatleyLake Charles$17K
- Robert VangossenLake Charles$14K
- Ryan ForetLake Charles$13K
- Keith LechtenbergLake Charles$13K
- Christine SmithBaton Rouge$185K
- Thomas DansbyMonroe$169K
- Michael FlemingShreveport$165K
- Robert St AmantGonzales$156K
- William HathawaySpringhill$105K
- Cesar GonzalesWest Monroe$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.